Indian Heart Journal, 2018 Background: Although conventional 60 mg of prasugrel allows for rapid and potent platelet inhibition within 30 min after loading dose, the efficacy and safety of lower doses of prasugrel in Indian patients has not yet been investigated.
Priti Kumari, Bhanwar Lal Ranwa
doaj +1 more source
Systematic review and meta-analysis of optimal P2Y₁₂ blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome [PDF]
, 2016 Background: Patients with diabetes are at increased risk of acute coronary syndromes (ACS) and their mortality and morbidity outcomes are significantly worse following ACS events, independent of other comorbidities.
Brown, Oliver I +2 more
core +2 more sources
Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. [PDF]
, 2012 The new anti-aggregating agent prasugrel is bioactivated by cytochromes P450 (CYP) 3A and 2B6. Ritonavir is a potent CYP3A inhibitor and was shown in vitro as a CYP2B6 inhibitor.
Ancrenaz, V. +6 more
core +2 more sources
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. [PDF]
, 2014 BackgroundThe choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond to clopidogrel, and low-cost generic ...
Boothroyd, Derek B +9 more
core +1 more source
Case study: Ticagrelor in plato and prasugrel in triton-timi 38 and trilogy-acs trials in patients with acute coronary syndromes [PDF]
, 2015 Copyrigh
Boersma, H. (Eric), Husted, S.
core +5 more sources
WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME
Рациональная фармакотерапия в кардиологии, 2018 The aim of the review is presenting the possibilities and perspectives of the third generation of thienopyridine P2Y12 receptor inhibitor prasugrel in the treatment of patients with acute coronary syndrome (ACS).
M. Yu. Gilyarov, Е. V. Konstantinova
doaj +1 more source
Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms [PDF]
Neurointervention, 2018 Thromboembolism is one of the major complications of stent assisted coiling in treatment of cerebral aneurysm. Clopidogrel resistance is so common and prasugrel is more effective in its rapid and potent effect.
Dongwhane Lee +4 more
doaj +1 more source
A hopeful therapy for Niemann-Pick C diseases [PDF]
, 2017 Not abstract ...
Erickson, Robert P. +1 more
core +1 more source
Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome [PDF]
, 2019 Objective: To assess whether cardiovascular events are increased after cessation of dual antiplatelet therapy (DAPT) following acute coronary syndrome (ACS) and to explore predictors for recurrent events after DAPT cessation during long-term follow-up.
Berry, Colin +3 more
core +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018 BackgroundEarly withdrawal of recommended antiplatelet treatment with clopidogrel adversely affects prognosis following percutaneous coronary interventions. Optimal antiplatelet treatment is essential following ST‐segment elevation myocardial infarction (
Konstantinos C. Koskinas +17 more
doaj +1 more source